NO20084882L - Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on - Google Patents

Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on

Info

Publication number
NO20084882L
NO20084882L NO20084882A NO20084882A NO20084882L NO 20084882 L NO20084882 L NO 20084882L NO 20084882 A NO20084882 A NO 20084882A NO 20084882 A NO20084882 A NO 20084882A NO 20084882 L NO20084882 L NO 20084882L
Authority
NO
Norway
Prior art keywords
crystalline forms
ribofuranosyl
thiazolo
pyrimidin
acetyl
Prior art date
Application number
NO20084882A
Other languages
English (en)
Norwegian (no)
Inventor
Michael Mutz
Casper Vogel
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38287962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084882(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of NO20084882L publication Critical patent/NO20084882L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
NO20084882A 2006-05-22 2008-11-20 Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on NO20084882L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80242506P 2006-05-22 2006-05-22
PCT/EP2007/054899 WO2007135134A1 (en) 2006-05-22 2007-05-21 Crystalline a and b forms of a maleate salt of 5-amino-3- (2 ', 3 '-di-o-acetyl-beta-d-ribofuranosyl) -3h-thiaz0l0 [4, 5-d] pyrimidin-2-one

Publications (1)

Publication Number Publication Date
NO20084882L true NO20084882L (no) 2008-12-17

Family

ID=38287962

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084882A NO20084882L (no) 2006-05-22 2008-11-20 Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on

Country Status (15)

Country Link
US (1) US20100286081A1 (zh)
EP (1) EP2027139A1 (zh)
JP (1) JP2009537603A (zh)
KR (1) KR20090029730A (zh)
CN (1) CN101528762A (zh)
AR (1) AR061024A1 (zh)
AU (1) AU2007253302A1 (zh)
CA (1) CA2652857A1 (zh)
CL (1) CL2007001427A1 (zh)
IL (1) IL195408A0 (zh)
MX (1) MX2008014891A (zh)
NO (1) NO20084882L (zh)
PE (1) PE20080179A1 (zh)
TW (1) TW200813081A (zh)
WO (1) WO2007135134A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019113A1 (en) * 2007-07-26 2009-01-28 Anadys Pharmaceuticals, Inc. New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one
PT2268642E (pt) 2008-04-23 2015-06-02 Gilead Sciences Inc Análogos de carba-nulceósidos 1¿-substituídos para tratamento antiviral
CA2773773C (en) 2009-09-21 2019-04-23 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
JP5937073B2 (ja) 2010-07-19 2016-06-22 ギリード・サイエンシズ・インコーポレーテッド ジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法
AU2011280910B2 (en) 2010-07-22 2015-07-09 Gilead Sciences, Inc. Methods and compounds for treating Paramyxoviridae virus infections
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
PL3230298T3 (pl) 2014-12-08 2021-06-14 F.Hoffmann-La Roche Ag 3-podstawione związki 5-amino-6h-tiazolo[4,5-d]pirymidyno-2,7-dionowe do leczenia i profilaktyki zakażenia wirusowego
SG10201912847QA (en) 2015-03-16 2020-02-27 Hoffmann La Roche Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
CN107743491B (zh) 2015-05-08 2020-08-21 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物
EP4001283A1 (en) 2015-05-12 2022-05-25 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
WO2017001307A1 (en) 2015-06-30 2017-01-05 F. Hoffmann-La Roche Ag Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
PT3785717T (pt) 2015-09-16 2022-04-14 Gilead Sciences Inc Métodos para o tratamento de infeções por coronaviridae
CN110139868B (zh) 2017-01-06 2021-07-09 豪夫迈·罗氏有限公司 制备3-取代的5-氨基-6H-噻唑并[4,5-d]嘧啶-2,7-二酮化合物的方法
ES2961460T3 (es) 2017-03-14 2024-03-12 Gilead Sciences Inc Métodos para tratar las infecciones por coronavirus felinas
AR111490A1 (es) 2017-05-01 2019-07-17 Gilead Sciences Inc Formas cristalinas de propanoato de (s)-2-etilbutil 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
AU2021234308C1 (en) 2020-03-12 2024-02-22 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
CN115362004A (zh) 2020-04-06 2022-11-18 吉利德科学公司 1’-氰基取代的碳核苷类似物的吸入制剂
JP2023528810A (ja) 2020-05-29 2023-07-06 ギリアード サイエンシーズ， インコーポレイテッド レムデシビル治療方法
EP4172160A2 (en) 2020-06-24 2023-05-03 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
TW202233204A (zh) 2020-08-27 2022-09-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50107047D1 (de) * 2000-04-06 2005-09-15 Siemens Ag Bereitstellen von ergänzenden diensten in einem paketvermittelnden kommunikationsnetz
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
DE60234376D1 (de) * 2001-11-27 2009-12-24 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimin-nucleoside und ihre verwendung
CA2537450C (en) * 2003-09-05 2012-04-17 Anadys Pharmaceuticals, Inc. Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
CA2566541C (en) * 2004-06-07 2012-10-09 Anadys Pharmaceuticals, Inc. 3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof

Also Published As

Publication number Publication date
CA2652857A1 (en) 2007-11-29
KR20090029730A (ko) 2009-03-23
MX2008014891A (es) 2009-01-29
US20100286081A1 (en) 2010-11-11
AR061024A1 (es) 2008-07-30
AU2007253302A1 (en) 2007-11-29
WO2007135134A1 (en) 2007-11-29
CN101528762A (zh) 2009-09-09
TW200813081A (en) 2008-03-16
CL2007001427A1 (es) 2008-05-16
IL195408A0 (en) 2011-08-01
JP2009537603A (ja) 2009-10-29
PE20080179A1 (es) 2008-04-22
EP2027139A1 (en) 2009-02-25

Similar Documents

Publication Publication Date Title
NO20084882L (no) Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on
FR17C1013I2 (fr) Pyrrolo[2,3-b]pyridines et pyrrolo[2,3-b]pyrimidines a substitution heteroaryle en tant qu'inhibiteurs de la janus kinase
NO20071095L (no) Hittil ukjente tiofenderivater
WO2007044407A3 (en) Pyrazolo (1 , 5a) pyrimidines as protein kinase inhibitors
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
NO20070723L (no) Progesteron reseptormodulatorer inneholdende pyrrol-oksindolderivater og deres anvendelse
WO2007058942A3 (en) Imidazopyrazines as protein kinase inhibitors
NO20093060L (no) Spirosykliske sykloheksanderivater
WO2005016528A3 (en) 6-substituted anilino purines as rtk inhibitors
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2007048065A3 (en) Pyrimidinones as casein kinase ii (ck2) modulators
ITRM20050265A1 (it) Protesi modulare perfezionata per osteosintesi, in particolare per l'osteosintesi dell'omero.
IL168102A0 (en) Chk-, pdk-and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
WO2008076883A3 (en) Triazine derivatives and their therapeutical applications
DK2004641T3 (da) HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
NO20090348L (no) Substituerte imidazolonderivater, sammensetninger og anvendelser av samme, samt fremgangsmater for fremstilling av samme
WO2007016352A3 (en) Oral liquid losartan compositions
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
DK1773796T3 (da) Oxopiperidinderivater, fremstilling deraf samt terapeutisk anvendelse deraf
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
DK1902054T3 (da) Pyrido[2,3-d]pyrimidinderivater, fremstilling og terapeutisk anvendelse heraf
NO20065898L (no) 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application